We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Beam Therapeutics Inc | NASDAQ:BEAM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 22.72 | 22.64 | 23.17 | 0 | 01:00:00 |
From May 2022 to May 2024
By Chris Wack
Beam Therapeutics Inc. said Friday that the U.S. Food and Drug Administration has lifted the clinical hold and cleared the Investigational New Drug application for BEAM-201 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.
The biotechnology company said its BEAM-201 is a specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.
"The FDA's clearance of our IND for BEAM-201 is an exciting moment for Beam and for the field of gene editing, as it represents the first IND clearance for a multiplex-base edited investigational drug," said John Evans, chief executive of Beam.
Beam shares were up 11% to $51 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 02, 2022 06:55 ET (11:55 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Beam Therapeutics Chart |
1 Month Beam Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
